Genmab A/S (OTCMKTS:GNMSF) Sees Large Volume Increase – Time to Buy?

Genmab A/S (OTCMKTS:GNMSF) shares saw an uptick in trading volume on Monday . 4,952 shares traded hands during mid-day trading, an increase of 154% from the previous session’s volume of 1,953 shares.The stock last traded at $320.00 and had previously closed at $310.6250.

Genmab A/S Trading Up 3.0%

The firm has a market capitalization of $19.70 billion, a price-to-earnings ratio of 25.10 and a beta of 0.77. The business’s fifty day moving average is $276.38 and its 200 day moving average is $278.56. The company has a quick ratio of 2.44, a current ratio of 2.46 and a debt-to-equity ratio of 0.81.

Genmab A/S Company Profile

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company’s core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab’s science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.